# Cardiogenic Shock

Ashley Cozart

---

## Definition

Impairment of cardiac output due to primary cardiac disorder that
    results in end-organ hypoperfusion and hypoxia

## Etiology

- Cardiomyopathic: myocardial infarction with LV dysfunction,
    exacerbation of heart failure, myocarditis, myocardial contusion,
    drug-induced
- Arrhythmic: atrial tachycardias (atrial fibrillation/flutter, AVRT,
    AVNRT), ventricular tachycardia and fibrillation, complete heart
    block, second degree heart block
- Mechanical: valvular insufficiency, valvular rupture, critical
    valvular stenosis, ventricular septal wall defect, ruptures
    ventricular wall aneurysm, atrial myxoma

## Presentation

- Cold (decreased perfusion) due to reduced cardiac output (can be
    wet- increased PCWP OR dry normal PCWP)
- Symptoms of volume overload + end-organ hypoperfusion (altered
    mental status, nausea, abdominal pain, decreased urine output)
- Hypotension; narrow pulse pressure

## Evaluation

- EKG
- Labs: CBC, CMP, BNP, troponin, lactate
- Evidence of end organ damage: lactic acidosis, acute kidney injury,
    acute liver injury
- Echocardiogram: assess EF and valves
- LHC If ischemia (see ACS)
- Hemodynamic monitoring via Swan-Ganz or PA catheter:
    - No benefit for general shock but does improve in-hospital mortality
    for those with cardiogenic shock
    - PA catheter hemodynamic profile:
        - Cardiac index \< 2.2, cardiac power \<0.6, SVR 800-1600, SVO2
        \<60%
        - LV-dominant: RA (CVP) \<15, PCWP \>18, PAPi \>1.5 (pulmonary
        artery pulsatility index)
        - RV-dominant: RA \>15, PCWP \<18, PAPi \>1.5
        - Bi-V-dominant: RA \>15, PCWP \>18, PAPi \>1.5
        - PAPi \< 1 indicates that patient will likely need RV support
        - CP \< 0.5 strongest independent hemodynamic correlate of
        mortality in CS
        - See right heart cath section for interpreting PA catheter
        profiles

## Management (medical & mechanical circulatory support)

### Medical management

Focus on optimizing preload, afterload, and contractility.

- Preload: IV diuresis
- Afterload: IV – nitroglycerine, nitroprusside; PO – hydralazine,
    isosorbide dinitrate; vasoconstricting pressors (phenylephrine,
    vasopressin) if needing BP support
- Contractility - Inodilators (increase contractility, decrease
    afterload – milrinone, dobutamine) or inoconstrictors (increase
    contractility and afterload – epinephrine, norepinephrine)

### Mechanical circulatory support indications

- Shock refractory to \>1 pressor
- Shock 2/2 MI (physiology: unloads LV, increases systemic perfusion,
    increases myocardial perfusion, and provides hemodynamic support
    during PCI)

Types of mechanical circulatory support (MCS)

<table>
<colgroup>
<col style="width: 6%" />
<col style="width: 25%" />
<col style="width: 22%" />
<col style="width: 22%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Intra-aortic Balloon Pump</th>
<th>V-A ECMO</th>
<th>Tandem Heart</th>
<th>Impella</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Dynamics</td>
<td>Inflates during diastole, deflates during systole</td>
<td>Blood from femoral vein is oxygenated and pumped to femoral
artery</td>
<td><p>LV: blood aspirated from LA to femoral artery</p>
<p>RV: blood aspirate from RA to PA</p></td>
<td><p>Impella 2.5, 5.0 &amp; CP: Blood aspirated from LV to aortic
root</p>
<p>Impella RP: Blood aspirated from IVC and delivered to PA</p></td>
</tr>
<tr class="even">
<td>Flow</td>
<td>1 LMP</td>
<td>4.5 LPM</td>
<td>4-5 LPM</td>
<td><p>2.5: 2.5 L/min</p>
<p>CP: 3.33 L/min</p>
<p>5.0: 5 L/min</p>
<p>RP: 4 L/min</p></td>
</tr>
<tr class="odd">
<td>Support</td>
<td>LV</td>
<td>BiV</td>
<td>LV, RV, or BiV</td>
<td>LV or RV (RP)</td>
</tr>
<tr class="even">
<td>Effects</td>
<td><p>Reduces afterload</p>
<p>Increases stroke volume (SV)</p>
<p>Increases coronary perfusion</p>
<p>Reduces LV preload and PCWP</p></td>
<td><p>Increases afterload</p>
<p>Reduces SV</p>
<p>Reduces LV preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
<td><p>Increases afterload</p>
<p>Reduces SV</p>
<p>Reduces LV preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
<td><p>Reduces SV</p>
<p>Reduces preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
</tr>
<tr class="odd">
<td>Complications</td>
<td><p>Thrombocytopenia</p>
<p>Thrombosis</p>
<p>Arterial obstruction</p>
<p>Aortic rupture or dissection</p>
<p>Air embolism</p></td>
<td><p>Circuit thrombosis</p>
<p>LV dilation</p>
<p>Hypothermia</p>
<p>Gas embolism</p></td>
<td><p>Tamponade d/t perforation</p>
<p>Thrombosis</p>
<p>Embolism (gas or thrombus)</p>
<p>Arterial Shunt</p></td>
<td><p>Pump migration</p>
<p>Hemolysis</p>
<p>Aortic regurg</p>
<p>LV perf</p>
<p>VT/VF</p></td>
</tr>
</tbody>
</table>

Daily management of MCS devices:

- Ensure optimal placement of device with daily CXR
- Anticoagulation (based on device)
- Hematoma monitoring at device site
- Check distal pulses to monitor for limb ischemia

Pearls for MCS

- MCS devices are contraindicated in following situations: aortic
    regurgitation or metallic aortic valve, aortic aneurysm or
    dissection, severe aortic or peripheral artery disease, left
    ventricular or left atrial thrombi, bleeding diathesis, uncontrolled
    sepsis
- ECMO is placed by the cardiac surgery team, once a patient is
    cannulated they will move onto the cardiac surgery team
- Impella, tandem heart, and IABPs are placed in the cath lab
- MCS is a bridge to recovery/definitive therapy, durable cardiac
    support (VAD), or transplant
